Abstract PR-05: Worsening disparities of racial minority participation in phase 1 early drug development trials in the United States, 2001-2018

Author(s):  
Hayley M. Dunlop ◽  
Evelyn Fitzpatrick ◽  
Kevin Kurti ◽  
Stephanie Deeb ◽  
Erin Gillespie ◽  
...  
Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
KM Wu ◽  
C Wu ◽  
J Dou ◽  
H Ghantous ◽  
S Lee ◽  
...  

2021 ◽  
pp. 107755872110166
Author(s):  
Gary Gaumer ◽  
Robert Coulam ◽  
Rose Desilets

This article examines minority participation in hospital senior management and how participation varies across areas in response to demographic and other market influences. We use data from Equal Employment Opportunity Commission, United States from 2008 to 2014 reported by private hospitals in the United States, grouped into 381 metropolitan areas. Analysis shows minority participation is sensitive to some local market factors including total population, share of minorities in the population, relative number of minorities with bachelor’s degrees in the population, and the concentration of local hospital markets. But, unlike markets for other hospital jobs (professionals, middle managers, and other jobs), changes in these factors create only small changes in minority participation for senior managers. Our results demonstrate that minority participation in senior management is not going to improve very much from future increases in minority populations and from educational parity. Public policies and deliberate organizational strategies will be required to make substantial improvements in diversity of senior management.


2018 ◽  
Vol 46 (S1) ◽  
pp. 50-58 ◽  
Author(s):  
Gregory W. Daniel ◽  
Monika Schneider ◽  
Marianne Hamilton Lopez ◽  
Mark B. McClellan

As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which combines a MER with payment reforms, transitioning from volume-based to “value-based” payments for antimicrobials. Here, the PAVE Award and similar MERs are reviewed, focusing on further refinement and avenues for implementation.


2011 ◽  
Vol 12 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Myra Rosen-Reynoso ◽  
Margarita Alegría ◽  
Chih-nan Chen ◽  
Mara Laderman ◽  
Robert Roberts

Author(s):  
Hiroshi Nakamura ◽  
Naohiko Wakutsu ◽  
Satoshi Murayama ◽  
Takeshi Suzuki

Sign in / Sign up

Export Citation Format

Share Document